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Amplification of the ErbB2 locus, which en-
codes a receptor tyrosine kinase, is common in
aggressive breast tumors and correlates with
poor prognosis. The mechanisms underlying
ErbB2-mediated breast carcinoma progression
remain incompletely defined. To examine the
role of the signaling and cell-adhesion receptor
b4 integrin during ErbB2-mediated tumorigene-
sis, we introduced a targeted deletion of the b4
signaling domain into a mouse model of ErbB2-
induced mammary carcinoma. Loss of b4 sig-
naling suppresses mammary tumor onset and
invasive growth. Ex vivo studies indicate that
b4 forms a complex with ErbB2 and enhances
activation of the transcription factors STAT3
and c-Jun. STAT3 contributes to disruption of
epithelial adhesion and polarity, while c-Jun is
required for hyperproliferation. Finally, deletion
of the b4 signaling domain enhances the effi-
cacy of ErbB2-targeted therapy. These results
indicate that b4 integrin promotes tumor pro-
gression by amplifying ErbB2 signaling and
identify b4 as a potential target for molecular
therapy of breast cancer.
INTRODUCTION
Breast cancer is the most common malignancy in women
and causes over 400,000 deaths per year (Parkin et al.,
2005). About 30% of all breast cancers carry amplifica-
tions of the ErbB2 locus, which encodes the receptor tyro-
sine kinase (RTK) ErbB2 (Slamon et al., 1987). These
tumors have an aggressive behavior, high rates of relapse,
and poor prognosis (Berger et al., 1988). In agreementwith the hypothesis that ErbB2 signaling initiates mam-
mary tumorigenesis, the levels of ErbB2 increase at the
onset of ductal carcinoma in situ (DCIS) (van de Vijver
et al., 1988). Furthermore, dimerization of ErbB2 induces
proliferation and suppresses apoptosis in MCF-10A
mammary epithelial acini, yielding solid multiacinar struc-
tures resembling DCIS (Muthuswamy et al., 2001). Finally,
transgenic mice expressing constitutively activated ErbB2
(Neu) in their mammary glands develop invasive ductal
carcinomas (Muller et al., 1988), directly implicating ErbB2
signaling in mammary oncogenesis.
Oncogene-induced hyperproliferation and suppression
of apoptosis are sufficient to induce luminal filling and
expansion of carcinoma in situ in glandular epithelia (Deb-
nath et al., 2002). Progression to invasive carcinoma, how-
ever, requires that cancer cells disassemble intercellular
junctions, reorientate their cytoskeletons, and finally in-
vade into the interstitial matrix. Certain oncogenic muta-
tions and combinations thereof can cause this gain in
motility in vitro, and studies with various cellular models
of tumor progression have identified a plethora of putative
pathogenic pathways (Thiery, 2002). However, the mech-
anisms by which ErbB2 amplifications or other oncogenic
lesions promote breast carcinoma progression in vivo
remain poorly understood.
Current insight into this problem derives largely from
studies on E-cadherin. E-cadherin mediates assembly of
adherens junctions and operates to restrain carcinoma in-
vasion. Lobular carcinomasof thebreastoftenexhibit loss-
of-function mutations of E-cadherin or methylation of its
promoter (Cavallaro and Christofori, 2004). Furthermore,
they often express elevated levels of the bHLH transcrip-
tion factor Twist, which silences the expression of E-cad-
herin as part of its proinvasive epithelial-to-mesenchymal
transition (EMT)program (Yangetal., 2004).However,com-
mon ductal carcinomas of the breast, including ErbB2-
positive tumors, often retain expression of E-cadherin
(Gamallo et al., 1993), suggesting that other mechanisms
candisrupt epithelial adhesion andpolarity in these tumors.Cell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc. 489
Studies of in vitro models suggest that the a6b4 integ-
rin—a component of hemidesmosomes—contributes to
oncogenesis by sustaining RTK signaling. b4 integrin sig-
naling proceeds through Src family kinase (SFK) mediated
phosphorylation of the cytoplasmic domain of b4, recruit-
ment of Shc, and activation of Ras and PI-3K (Mainiero
et al., 1997; Shaw et al., 1997). The RTKs ErbB2, EGF-R,
and Met associate with a6b4, and there is evidence
suggesting that they promote invasive signaling through
phosphorylation of b4 (Falcioni et al., 1997; Mariotti
et al., 2001; Trusolino et al., 2001). Accordingly, wild-
type, but not signaling-defective, b4 causes a gain in inva-
sive ability in a breast carcinoma cell line expressing Met
(Shaw et al., 1997). In spite of this body of work, the hy-
pothesis that a6b4 has a protumorigenic function remains
controversial. Expression of wild-type, but not signaling-
defective, b4 activates p53 and induces cell-cycle arrest
and apoptosis in rectal carcinoma cells (Bachelder et al.,
1999). Furthermore, antibody blockage of a6b4 disrupts
mammary epithelial polarity and promotes hyperprolifera-
tion in 3D Matrigel (Weaver et al., 1997). These complex
and apparently contrasting effects of a6b4 may reflect
physiologically distinct roles of this integrin in different
cancer cells or intrinsic limitations of these models.
Given the complexity of tumor progression, it is impor-
tant to use experimental models that closely mimic the
evolution of humanbreast cancer while allowingmolecular
manipulation. DNA microarray data reveal that the basal-
like ductal breast carcinomas and related ErbB2-positive
tumors often express high levels of b4 (Sorlie et al.,
2001). To examine whether b4 signaling plays a role in
ErbB2-mediated mammary tumorigenesis, we have intro-
duced a targeted deletion of the b4 signaling domain in
MMTV-Neu mice. By combining in vivo analysis with an
ex vivoRNAi knockdown/reconstitution approach,wepro-
vide evidence that b4 combines with ErbB2 and amplifies
its signaling ability, enablingmammary tumor progression.
RESULTS
Deletion of the b4 Signaling Domain Suppresses
ErbB2-Driven Mammary Gland Tumorigenesis
Mice carrying a targeted deletion of the b4 signaling do-
main (b41355T/1355T; see Figure S1 in the Supplemental
Data available with this article online) exhibit defects in
wound healing and postnatal angiogenesis, consistent
with the observation that this mutation does not impair
a6b4-dependent adhesion or assembly of hemidesmo-
somes but suppresses b4 signaling (Nikolopoulos et al.,
2004, 2005). Whole-mount analysis of ductal outgrowth
and immunostaining studies suggest that b41355T/1355T
female mice undergo normal mammary gland morpho-
genesis (Figure S2). In addition, these mice are able to
nurse their progeny effectively. These results indicate
that loss of b4 signaling does not cause obvious defects
in mammary gland development.
To examine the role of b4 signaling in mammary tumor-
igenesis, we introduced the b4-1355T mutation in MMTV-490 Cell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc.Neu(YD) mice, which progress rapidly from ductal carci-
noma in situ to invasive and metastatic carcinoma
(Dankort et al., 2001), allowing an examination of the role
of b4 signaling during tumor progression. MMTV-
Neu(YD);b41355T/1355T (henceforth Neu(YD)/b4-1355T) mice
developedpalpable tumors significantly later as compared
to control MMTV-Neu(YD);b4+/+ (Neu(YD)/b4-WT) mice:
Median tumor onset was delayed by approximately
50% in b4 mutant mice (Figure 1A). Moreover, they dis-
played significantly fewer tumors as compared to control
mice (Figure 1B). Finally, Neu(YD)/b4-1355T mice ex-
hibited greatly reduced cumulative tumor burden at 17
and 22 weeks of age (Figure 1C). Heterozygous MMTV-
Neu(YD);b4+/1355T mice exhibited an intermediate pheno-
type (Figure 1A; cumulative tumor burden at 22 weeks:
7.1 g ± 2.1 SD, n = 6), suggesting that b4 signaling is
haploinsufficient for mammary tumor onset and growth.
Together, these results indicate that deletion of the b4
signalingdomain inhibits ErbB2-initiatedmammary tumor-
igenesis.
b4 Signaling Promotes Tumor Cell Proliferation
and Suppresses Apoptosis
Neoplastic cells in mammary intraepithelial neoplasia
(MIN) lesions of Neu(YD)/b4-WT mice had significantly
elevated levels of b4 as compared to normal luminal cells
(Figure S3A). b4 was no longer concentrated at the base-
ment-membrane junction but was instead diffusely dis-
tributed over the cell surface. The levels of its basement-
membrane ligand, laminin-5, were severely reduced. As
MIN lesions progressed to invasive carcinomas, laminin-
5 became undetectable, but b4 remained elevated
(Figure S3B). The tumors of Neu(YD)/b4-1355T mice ex-
hibited a similar upregulation of b4 and downregulation
of laminin-5. However, mutant b4 remained in part con-
centrated at the basement-membrane junction in MIN
lesions of these mice (Figure S3A), suggesting that b4 sig-
naling may disrupt epithelial polarity.
Since established tumors of Neu(YD)/b4-1355T mice
grew only at a modestly reduced rate (approximately
70% of control value; see Figure 1G and below) and
were vascularized to the same extent as those of control
Neu(YD)/b4-WT mice (Figure S4), we examined whether
loss of b4 signaling inhibits mammary tumor induction or
initial growth. Neu(YD)/b4-1355T mice exhibited signifi-
cantly fewer MIN lesions at 13 weeks of age (2.1 ± 2.4
per median longitudinal section, n = 7 mice) as compared
to Neu(YD)/b4-WT mice (10.1 ± 6.6, n = 8 mice, p = 0.01),
indicating that loss of b4 signaling inhibits mammary
tumor onset and initial growth.
To dissect the mechanism by which loss of b4 signaling
suppresses mammary tumorigenesis, preneoplastic and
MIN lesions were stained with anti-Ki-67. As shown in
Figure 1D, activated ErbB2 induced robust epithelial cell
proliferation prior to overt morphological transformation
in the ducts and lobules of Neu(YD)/b4-WT mice (age-
matched wild-type mice contained only scattered Ki-67+
cells). By contrast, cell proliferation was only modestly
Figure 1. Deletion of the b4 Integrin Signaling Domain Suppresses ErbB2-Initiated Mammary Tumorigenesis
(A) Kaplan-Meier analysis of tumor onset. b4-WT versus b4-1355T: p < 0.0001 by the log-rank test.
(B) Average number (±SD) of mammary glands containing palpable tumors per mouse per genotype at the indicated ages. After 13 weeks, p < 0.01.
(C) Average cumulative tumor burden (±SD) for each cohort at 17 and 22 weeks of age.
(D) Sections of mammary fat pads from 13-week-old mice of the indicated genotype were stained with anti-Ki-67. Representative images of ducts,
lobules, and MIN lesions are shown. Scale bar = 50 mm. The graphs show the mean percentage of Ki-67 positive cells (±SD) in ducts and lobules (top,
n = mice) and MIN lesions (bottom, n = MIN lesions from four mice).
(E) Consecutive sections of early MIN lesions from 13-week-old mice of the indicated genotype were stained with anti-cleaved caspase-3 (Casp.3*)
and anti-Ki-67. Representative images are shown. Scale bar = 50 mm.
(F) Percentages of tumors in each category (WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated) in 5-month-old mice of
the indicated genotype.
(G) Mice were sacrificed approximately 7.5 weeks after detection of their first palpable tumor. Sagittal lung sections (2–4 per mouse) were stained
with hematoxylin and eosin (H&E) and examined microscopically. The graph on the left shows the percentage of mice of the indicated genotype
with <1, 1–5, or >5 metastases per lung section. The graph on the right shows the mean cumulative tumor burden (±SD) in each cohort of mice at
the time of euthanasia.increased in the ducts and lobules of Neu(YD)/b4-1355T
mice. Furthermore, MIN lesions of Neu(YD)/b4-WT mice
contained a significantly higher proportion of proliferatingtumor cells (approximately 40%) than those of Neu(YD)/
b4-1355T mice (approximately 20%) (Figure 1D). Staining
with antibodies to cleaved caspase-3 indicated modestCell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc. 491
apoptotic rates in most MIN lesions of Neu(YD)/b4-WT
mice. However, a subset of early MIN lesions with a pervi-
ous lumen in Neu(YD)/b4-1355T mice contained a signifi-
cant number of apoptotic cells (8.9% ± 4.4%, n = 4) (Fig-
ure 1E). Interestingly, these lesions had a high proliferative
index, suggesting that aberrant cell proliferation contrib-
utes to apoptosis in these lesions. By contrast, early MIN
lesions with a similarly high proliferative rate in Neu(YD)/
b4-WT mice exhibited only modest apoptosis (1.8% ±
0.7%, n = 4, p = 0.02) (Figure 1E). These results suggest
that b4 signaling promotes cell proliferation throughout
the preneoplastic and the MIN stage and suppresses
oncogene-induced apoptosis prior to luminal filling.
Deletion of the b4 Signaling Domain Inhibits Tumor
Progression and Metastasis
ErbB2 mammary tumors progress from MIN to invasive
carcinoma through steps characterized by increasing
degrees of dedifferentiation (Figure S5A). At 5 months
of age, Neu(YD)/b4-1355T mice exhibited a high propor-
tion of well-differentiated and moderately differentiated
tumors characterized by a glandular appearance. By con-
trast, Neu(YD)/b4-WT mice had developed predominantly
poorly differentiated tumors (Figure 1F), suggesting that
deletion of the b4 signaling domain inhibits histological
progression. Since mammary tumors of MMTV-Neu(YD)
mice primarily metastasize to the lung (Dankort et al.,
2001), we examined the lungs of both types of mice 7.5
weeks after primary tumor onset. Most Neu(YD)/b4-WT
mice had developed a large number of metastases, but
many Neu(YD)/b4-1355T mice exhibited either no metas-
tases or only a few of them (Figure 1G, left). Cumulative
primary tumor burden was similar in the two types of
mice (Figure 1G, right). These results suggest that loss
of b4 signaling inhibits tumor invasion and metastasis.
To further examine theeffectofb4signalingon tumorpro-
gression, moderately differentiated tumors from Neu(YD)/
b4-WT and Neu(YD)/b4-1355T mice were stained with
antibodies toE-cadherin and the tight-junction component
ZO-1. As shown in Figure S5B, both types of tumors
retained expression of E-cadherin at the cell surface. How-
ever, tumors fromNeu(YD)/b4-WTmice exhibited severely
decreased ZO-1 staining. Tight-junction strands were not
apparent, and most of the ZO-1 reactivity was located ec-
topically in intracellular vesicles. By contrast, tumors from
Neu(YD)/b4-1355T mice contained clear tight-junction
strands between adjacent cells (Figure S5B), suggesting
that b4 signaling promotes disassembly of tight junctions.
b4 Signaling Disrupts Mammary Epithelial Adhesion
and Polarity In Vitro
Tight junctions have emerged as key regulators of mam-
malian epithelial adhesion and polarity (Macara, 2004).
To examine the effect of b4 signaling on epithelial adhe-
sion and polarity, we isolated primary ErbB2-transformed
cells from Neu(YD)/b4-WT and Neu(YD)/b4-1355T mice
and verified that they expressed similar levels of ErbB2
(Figure 2A). Whereas tumor cells expressing wild-type492 Cell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc.b4 exhibited a spindle-like morphology and overlapping
margins, those expressing b4-1355T had polygonal
shapes and closely apposed margins. Consistent with
their morphology, cells expressing wild-type b4 had se-
verely disrupted tight junctions and disorganized adhe-
rens junctions (Figure 2B). Strikingly, tumor cells express-
ing b4-1355T exhibited well-organized cell junctions
(Figure 2B), indicating that loss of b4 signaling restores
epithelial adhesion in ErbB2-transformed mammary epi-
thelial cells (MECs). Gefitinib (Iressa), which was devel-
oped to block EGF-R but also inhibits ErbB2 with an
IC50 of approximately 1 mM (Figure S6A; Moasser et al.,
2001), promoted reassembly of adherens and tight junc-
tions in tumor cells expressing wild-type b4 (Figure 2B).
Since ErbB2-transformed MECs do not express detect-
able levels of EGF-R in vitro (Figure S6B), it is likely that
Iressa exerts its effect in these cells by inhibiting ErbB2.
These results suggest that the b4 integrin cooperates
with ErbB2 to induce disruption of epithelial adhesion.
Studies ofMECs in organotypic 3DMatrigel culture have
highlighted the contribution of epithelial adhesion and
polarity to growth inhibition (Bissell et al., 2003). As antic-
ipated, tumor cells expressing wild-type b4 formed ex-
pansive solid spheroids in 3D Matrigel (Figure 2C). Immu-
nofluorescence staining showed that these structures
were profoundly disorganized. Laminin-5 was deposited
both around and inside tumor cell aggregates, and the
b4 integrin was diffusely distributed over the cell surface
(Figure 2D). In addition, E-cadherin and b-catenin were
not concentrated at adherens junctions (unpublished
data), and ZO-1 was present in intracellular vesicles
(Figure 2D). In striking contrast, most tumor cells express-
ing b4-1355T assembled pseudoacinar structures (Fig-
ure 2C). These structures possessed a lumen and ex-
hibited a distinctive epithelial organization and polarity.
Themutant integrin was concentrated at the basal cell sur-
face, and laminin-5 was deposited exclusively underneath
this surface (Figure 2D). E-cadherin and b-catenin were
partially localized at cell-to-cell junctions (unpublished
data), andZO-1was concentrated in tight-junction strands
at the apical junctional complex (Figure 2D). Thus, loss of
b4 signaling restores a significant degree of epithelial
polarity to ErbB2-transformed MECs.
To examine the effect of b4 signaling on growth control,
we monitored tumor cell proliferation in 3D Matrigel. Over
an 11 day period, the disorganized aggregates consisting
of tumor cells expressing wild-type b4 expanded continu-
ously. By contrast, the pseudoacinar spheroids formed by
cells expressing mutant b4 underwent a very limited ex-
pansion (Figure S7), indicating that b4 signaling is required
for ErbB2-induced epithelial hyperproliferation. These re-
sults suggest that b4 signaling contributes to disrupt
both epithelial organization and growth control.
The b4 Integrin Disrupts Epithelial Organization
by a Direct Signaling Mechanism
Because b4 signaling promotes tumor cell proliferation at
theMIN stage, it may favor the accumulation of secondary
Figure 2. Ex Vivo Analysis of Epithelial Adhesion and Polarity
(A) Four populations of primary Neu(YD)/b4-WT (W1–W4) and Neu(YD)/b4-1355T (T1–T4) tumor cells were isolated and subjected to immunoblotting
with anti-b4 and anti-ErbB2.
(B) Primary tumor cells (n = 3 per genotype) were cultured on collagen I in the presence of 5% FBS overnight and subjected to staining with anti-ZO-1
or double staining with anti-E-cadherin (E-cad) and anti-b-catenin (b-cat) followed by counterstaining with DAPI. The insets show wild-type cells
treated overnight with 10 mM Iressa. Scale bar = 25 mm.
(C) W1–W5 and T1–T5 cells were cultured in 3D Matrigel in serum-free medium for 13 days. The upper panels show phase-contrast images of W3
and T1 cells. Scale bar = 50 mm. The graph shows the percentages (±SD) of pseudoacini formed by each primary tumor cell population in 3DMatrigel.
T4 cells formed solid aggregates in Matrigel. However, Iressa only partially restored cell junctions in these cells (unpublished data), suggesting that
they had accumulated genetic lesions able to disrupt cell polarity independently of ErbB2 signaling.
(D) 3D Matrigel cultures (n = 3 per genotype) were fixed at day 13, sectioned, and stained as indicated. Scale bar = 50 mm.mutations driving tumor progression. To examine whether
the b4 integrin disrupts epithelial adhesion by a direct
signaling mechanism, we used an RNAi-reconstitution
strategy to generate isogenic Neu-transformed MECs
expressing either wild-type or mutant b4 (Figure 3A).
Notably, whereas the Neu-b4-WT cells failed to organize
adherens and tight junctions, the Neu-b4-1355T cells as-
sembled both types of junctions in culture (Figure S8A).
Iressa restored junction formation in Neu-b4-WT cells
(Figure S9C). These results suggest that the b4 integrin in-
duces disruption of cell junctions by a direct signaling
mechanism.
Constitutively active RTKs and SFKs can induce dis-
assembly of adherens junctions through Snail/Slug-
mediated repression of E-cadherin or tyrosine phosphor-ylation and endocytosis of the E-cadherin/b-catenin com-
plex (Thiery, 2002). Studies with inhibitors suggested that
ErbB2 disrupts epithelial adhesion in Neu-b4-WT cells
through SFK signaling (Figure S9C), but not through acti-
vation of PI-3K or MMP 1, 2, 3, and 9 (unpublished
data). We did not, however, detect reduced expression
of E-cadherin or b-catenin in Neu-b4-WT cells. In addition,
b-catenin was phosphorylated on tyrosine to similar levels
in Neu-b4-WT and Neu-b4-1355T cells (Figure S8B).
These experiments suggest that b4 enables ErbB2 to dis-
rupt epithelial adhesion through a novel mechanism.
To examine the effect of b4 signaling on mammary
tumor architecture, Neu-b4-WT and Neu-b4-1355T cells
were implanted in the mammary fat pad of athymic nude
mice. Over a 3 week period, Neu-b4-WT cells formedCell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc. 493
Figure 3. The b4 Integrin Disrupts Epithelial Adhesion and Induces Hyperproliferation by a Direct Signaling Mechanism
(A) Primary tumor cells fromMMTV-Neu(YD)mice lost expression of Neu after 3–4 passages in culture andwere then rescuedwith an activated form of
ErbB2 (Neu). These cells were then infected with retroviral vectors encoding either human b4-WT or b4-1355T in combination with a shRNA designed
to selectively knock down endogenous mouse b4. Equal amounts of total proteins were subjected to immunoblotting with anti-b4 or anti-ErbB2.
(B) Neu-b4-WT and Neu-b4-1355T cells were implanted in the mammary fat pad of athymic nudemice. The graph shows themean tumor weight ± SD
at day 23.
(C) Orthotopic tumors were sectioned and subjected to H&E staining. Representative pictures are shown (n = 8). Scale bar = 50 mm.
(D) Orthotopic tumors were stained as indicated (n = 4). Dotted lines were drawn along the basement membrane of pseudoglandular structures. Scale
bars = 50 mm.tumors approximately 2-fold larger than those generated
by Neu-b4-1355T cells (Figure 3B). Tumors expressing
wild-type b4 had a solid histological appearance and
lacked signs of tissue organization (Figure 3C). Immuno-
fluorescence staining detected scattered, short fibrils of
laminin-5 (Figure 3D) and collagen IV (unpublished data).
b-catenin was diffusely distributed near the cell surface
(unpublished data), and ZO-1 was predominantly present
in intracellular vesicles (Figure 3D). By contrast, tumors
expressing mutant b4 exhibited a striking pseudoglandu-
lar organization (Figure 3C). The epithelial cells surround-
ing the lumens of glandular structures were supported
by a continuous, albeit partially disorganized, basement
membrane containing laminin-5 (Figure 3D) and collagen
IV (unpublished data). They exhibited many seemingly
normal b-catenin-containing junctions (unpublished
data) and assembled ZO-1-containing tight junctions to-494 Cell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc.ward their apical pole (Figure 3D). Staining with antibodies
to Ki-67 and to cleaved caspase-3 showed that Neu-b4-
1355T tumors contained significantly fewer proliferating
cells and more apoptotic cells as compared to Neu-b4-
WT tumors (Figure 3D). Notably, the apoptotic cells in
Neu-b4-1355T tumors were concentrated in the lumens
of pseudoglandular structures, indicating that b4 signaling
suppresses anoikis. These results illustrate the ability of b4
signaling to coordinately disrupt epithelial polarity and
growth control in vivo.
b4 Signaling Promotes Mammary Tumor Cell
Proliferation and Invasion
To further study the effect of b4 signaling on ErbB2-
mediated proliferation and invasion, we examined the be-
havior of Neu-b4-WT and Neu-b4-1355T cells in vitro. In
the absence of serum, theNeu-b4-1355T cells proliferated
Figure 4. b4 Signaling Promotes Tumor Cell Proliferation, Invasion, and Metastasis
(A) Cells were cultured on collagen I in serum-free medium (SFM) or with 10% FBS. Triplicate samples were counted at the indicated times. Error bars
represent SD.
(B) Cells were cultured on collagen I under sparse conditions with SFM or 10% FBS (FBS) or at confluency with 10% FBS (FBS confluent) in the pres-
ence of BrdU for 24 or 28 hr, respectively. The graph shows the percentage of BrdU+ cells (±SD for SFM and FBS).
(C) Cells were seeded at low density on collagen I and cultured in complete medium for 2 days. Scale bar = 50 mm.
(D) Cells treatedwith Iressa (10 mM) or vehicle alone (DMSO) were subjected toMatrigel invasion assay in response to FBS. The graph shows themean
number of invaded cells (±SD) per microscopic field from triplicate samples. The bottom panels show representative fields. Scale bar = 50 mm.
(E) Cells were injected in the tail vein of nude mice. Percentages of lung section areas occupied by metastases (±SD) were quantified 30 days later by
image analysis. Bottom panels show representative images of sagittal lung sections. Scale bar = 2 mm.at a dramatically reduced rate in comparison to Neu-b4-
WT cells (Figures 4A and 4B). In the presence of serum,
both types of cells proliferated at similar rates during the
initial phase of growth. However, upon reaching conflu-
ency, the Neu-b4-1355T cells proliferated less rapidly as
compared to control Neu-b4-WT cells (Figures 4A and
4B). These results suggest that b4 signaling enables acti-
vated ErbB2 to promote growth-factor-independent mito-
genesis and contributes to a certain extent to its ability to
disrupt contact inhibition.
Consistent with their inability to form cell-to-cell junc-
tions, Neu-b4-WT cells scattered extensively in culture.
In contrast, the Neu-b4-1355T cells grew as clusters of
tightly adhering cells (Figure 4C). When subjected to
Matrigel invasion assay, the Neu-b4-WT cells invaded
efficiently, and Iressa prevented their invasion. In contrast,
the Neu-b4-1355T cells invaded poorly through Matrigel
(Figure 4D). Finally, upon intravenous injection in athymic
nude mice, Neu-b4-WT cells produced numerous, large
metastases in the lung, but Neu-b4-1355T formed only
a few micrometastases (Figure 4E). Together with the ob-servation that Neu(YD)/b4-1355T mice progress to lung
metastasis less efficiently than Neu(YD)/b4-WT mice
(Figure 1G), these results indicate that b4 signaling pro-
motes mammary tumor invasion and metastasis.
The b4 Integrin Amplifies ErbB2 Signaling
Biochemical studies were performed to examine the
molecular mechanism by which b4 signaling promotes
mammary tumorigenesis. Coimmunoprecipitation analy-
sis of Neu-b4-WT cells indicated that ErbB2 forms a com-
plex with a6b4 and induces tyrosine phosphorylation of
b4 (Figure 5A). Whereas Iressa suppressed tyrosine phos-
phorylation of both ErbB2 and b4, PP2 suppressed
phosphorylation of b4 but only partially inhibited phos-
phorylation of ErbB2 (Figure 5A), suggesting that ErbB2
induces phosphorylation of b4 through SFKs. Notably, for-
mation of the b4-ErbB2 complex and tyrosine phosphory-
lation of b4 did not require ligand binding to a6b4 (un-
published data) or the kinase activity of ErbB2 or SFKs
(Figure 5A). Comparative coimmunoprecipitation of Neu-
b4-WT and Neu-b4-1355T cells revealed that deletion ofCell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc. 495
Figure 5. The b4 Integrin Associates with ErbB2 and Amplifies Its Signaling Capacity
(A) Neu-b4-WT cells (WT) were cultured on collagen I in SFM and left untreated or treated with Iressa (10 mM) or PP2 (10 mM) for 90min. Equal amounts
of total proteins were immunoprecipitated by anti-b4 or control anti-MHC I mAb and subjected to immunoblotting with anti-ErbB2, anti-P-Tyr, or anti-
b4. Total cell lysates containing equal amounts of proteins were subjected to immunoblotting with the indicated antibodies
(B) Equal amounts of total proteins from the indicated cells were immunoprecipitated with control anti-MHC I mAb (ctrl), anti-b4 mAb, or anti-ErbB2
mAb. Samples were subjected to immunoblotting with the indicated antibodies. Total lysates containing equal amounts of proteins were subjected to
immunoblotting with anti-b4 and anti-ErbB2.
(C) The indicated cells were cultured in SFMand left untreated or treatedwith Iressa (10 mM), PP2 (10 mM), or both compounds for 90min. Total lysates
containing equal amounts of proteins were subjected to immunoblotting with the indicated antibodies.
(D) The indicated cells were cultured on collagen I in SFM and stained with anti-phospho-JNK and DAPI. Scale bars = 25 mm.
(E) The indicated cells were starved and plated on laminin-5 (Lam-5) or collagen I (Coll I) in SFM for 85 min. Equal amounts of proteins were subjected
to immunoblotting with the indicated antibodies.
(F) Model of joint b4-ErbB2 signaling.the b4 signaling domain uncouples a6b4 from ErbB2 and
inhibits activation of integrin-associated SFKs. In addition,
it reduces the amount of SFKs associated with ErbB2
(Figure 5B). These results indicate that the b4 signaling
domain is required for assembly of the b4-ErbB2 complex
and promotes SFK association with ErbB2.
Since SFKs can phosphorylate Y845 in the P loop of
EGF-R (Ishizawar and Parsons, 2004), we examined the
effect of SFK inhibition on phosphorylation of the corre-
sponding tyrosine in the P loop of ErbB2. Immunoblotting
of total lysates showed that PP2 and Iressa partially inhibit
phosphorylation of the P loop of ErbB2 and, when used in
combination, completely suppress phosphorylation of this
site (Figure 5C). Similar results were obtained upon replac-496 Cell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc.ing PP2 with dasatinib, which inhibits SFKs at nanomolar
concentrations (Figure S9A). Deletion of the b4 signaling
domain inhibited phosphorylation of the P loop but not
the major autophosphorylation site of ErbB2 (Figure 5C),
suggesting that the b4 signaling domain contributes to
phosphorylation of the P loop of ErbB2 by promoting
SFK association with the RTK (see Figure 5F for a model).
Thus, b4 functions both upstream and downstream of
ErbB2, and deletion of the b4 signaling domain uncouples
b4 from ErbB2, suppressing joint signaling.
To confirm the role of SFKs in b4-ErbB2 signaling, Neu-
b4-WT cells were treated with dasatinib, which inhibits
SFKs and also Abl, or with Gleevec, which inhibits Abl but
not SFKs. Dasatinib suppressed tumor cell proliferation
and restored assembly of cell junctions, whereas Gleevec
did not exert these effects (Figures S9B and S9C), provid-
ing additional evidence that SFKs play a key role in joint
b4-ErbB2 signaling.
b4 Signaling Controls Activation of c-Jun and STAT3
To examine the effect of b4 on downstream signaling, we
studied the activation of ERK, JNK, and Akt in Neu-b4-WT
and Neu-b4-1355T cells stably adhering to laminin-5 or
collagen I. These kinases were found to be activated to
similar levels in both types of cells on either substrate
(Figure S10). Since b4 integrin signaling promotes nuclear
translocation of MAP kinases (Nikolopoulos et al., 2005),
we monitored nuclear accumulation of activated ERK
and JNK in Neu-b4-WT and Neu-b4-1355T cells. Immuno-
fluorescence staining did not reveal significant differences
in nuclear accumulation of activated ERK between the
two types of cells (unpublished data). However, whereas
P-JNK accumulated in the nucleus in Neu-b4-WT cells,
it was diffusely distributed in the cytoplasm in Neu-b4-
1355T cells (Figure 5D), suggesting that b4 signaling con-
trols nuclear translocation of activated JNK. In agreement
with this conclusion, phosphorylation of c-Jun at its JNK
phosphorylation site, S63, was substantially suppressed
in Neu-b4-1355T cells plated on either laminin-5 or colla-
gen I (Figure 5E). In addition, both Iressa and dasatinib
inhibited phosphorylation of c-Jun in Neu-b4-WT cells
(Figures S9A and S11). These results indicate that b4 con-
tributes to ErbB2 signaling by promoting nuclear translo-
cation of JNK and therefore phosphorylation of c-Jun.
Prior studies have linked SFK-mediated phosphoryla-
tion of the P loop of ErbB receptors to JAK-STAT signaling
(Ishizawar and Parsons, 2004). We therefore examined the
effect of deletion of the b4 signaling domain on STAT3
activation. Whereas STAT3 was constitutively phosphory-
lated at its activation site, Y705, in Neu-b4-WT cells plated
on laminin-5 or collagen I, phosphorylation of this residue
was almost undetectable in Neu-b4-1355T cells on either
matrix ligand (Figure 5E). Furthermore, Iressa and dasati-
nib inhibited phosphorylation of Y705 in Neu-b4-WT cells
(Figures S9A and S11). These results indicate that deletion
of the b4 signaling domain impairs ErbB2-mediated acti-
vation of STAT3.
To examine phosphorylation of c-Jun andSTAT3 in vivo,
sections ofmammary glands from 13-week-oldmicewere
stained with anti-P-c-Jun and anti-PY-STAT3. Most pre-
neoplastic and tumor cells in MIN lesions of Neu(YD)/b4-
WT mice exhibited prominent nuclear staining for acti-
vated c-Jun and STAT3. In contrast, only few epithelial
cells in similar lesions from Neu(YD)/b4-1355T mice dis-
played strong nuclear staining (Figure S12A). Immuno-
blotting of mammary fat-pad lysates confirmed the reduc-
tion of c-Jun phosphorylation in the lesions of Neu(YD)/
b4-1355T mice (Figures S12B and S12C). The phosphor-
ylation of STAT3 in glandular epithelium could not be
accurately quantified by immunoblotting because of
the prominent activation of STAT3 in stromal cells (Fig-
ure S12A). Together, these results indicate that the b4 in-tegrin enables ErbB2 to activate c-Jun and STAT3
(Figure 5F).
c-Jun Is Necessary for Hyperproliferation and STAT-
3 for Disruption of Epithelial Adhesion and Invasion
To examine the role of c-Jun during ErbB2-driven mam-
mary tumorigenesis, we used the dominant-negative
mutant TAM67, which suppresses breast cancer cell pro-
liferation by interfering with AP-1-dependent transcription
(Ludes-Meyers et al., 2001). Neu-b4-WT cells were trans-
duced with a retroviral vector encoding TAM67 or GFP as
a control (Figure 6A). Expression of TAM67 inhibitedmam-
mary tumor cell proliferation in vitro (Figure 6B) and tumor-
igenicity in vivo (Figure 6C). It did not, however, restore
assembly of tight or adherens junctions (Figure 6D) or
suppress the ability of Neu-b4-WT cells to invade through
Matrigel in vitro (Figure 6E). These results suggest that
c-Jun is necessary for ErbB2-mediated hyperproliferation
but not for disruption of epithelial adhesion.
Recent studies have indicated that STAT3 activation is
sufficient to transform mammary epithelial cells in vitro
(Dechow et al., 2004). Expression of the dominant-nega-
tive mutant STAT3b (Caldenhoven et al., 1996) (Figure 6A)
did not inhibit mammary tumor cell proliferation in vitro
(Figure 6B) or tumorigenicity in vivo (Figure 6C). However,
it restored assembly of tight junctions to a significant
extent and formation of adherens junctions partially (Fig-
ure 6D). In addition, STAT3b inhibited Matrigel invasion
(Figure 6E) and experimental metastasis (Figure 6F).
These results suggest that STAT3 promotes ErbB2-medi-
ated disruption of cell junctions and invasion but not hy-
perproliferation.
To confirm the effects of dominant-negative constructs,
Neu-b4-WT cells were transduced with lentiviral vectors
encoding shRNAs targeting c-Jun or STAT3 (Figure S13A).
Knockdown of c-Jun suppressed tumor cell hyperprolifer-
ation but did not restore assembly of tight junctions. By
contrast, knockdown of STAT3 partially restored assem-
bly of tight junctions without affecting proliferative rates
(Figures S13B and S13C). Collectively, these data argue
that the b4-ErbB2 complex promotes hyperproliferation
through activation of c-Jun and disrupts epithelial adhe-
sion largely through activation of STAT3.
Deletion of the b4 Signaling Domain Improves
the Efficacy of Anti-ErbB2 Therapy
Because of its ability to sustain oncogenic signaling, the
b4 integrin may promote tumor resistance to anti-ErbB2
targeted therapy. To explore this possibility, we compared
the therapeutic efficacy of Iressa in Neu(YD)/b4-WT and
Neu(YD)/b4-1355T mice. Iressa was chosen because it in-
hibits rat ErbB2 effectively (Figure S6) and suppresses the
proliferation of breast cancer cells overexpressing ErbB2
(Moasser et al., 2001). In addition, although the tumors
arising in MMTV-Neu mice contain low levels of EGF-R,
it does not appear to be activated (Figure S6C), sug-
gesting that Iressa can specifically suppress ErbB2 in
these tumors. The humanized anti-ErbB2 mAb HerceptinCell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc. 497
Figure 6. b4 Signaling Promotes Tumor Cell Hyperproliferation through c-Jun and Disruption of Epithelial Adhesion and Invasion
through STAT3
(A) Neu-b4-WT (b4-WT) cells transduced with retroviral vectors encoding GFP, TAM67, or STAT3bwere subjected to immunoblotting with antibodies
reacting with TAM67 and endogenous c-Jun (top) or STAT3b and endogenous STAT3 (a) (bottom).
(B) b4-WT cells expressing GFP alone or in combination with TAM67 or STAT3b and Neu-b4-1355T cells (b4-1355T) expressing GFP alone were
cultured on collagen I in serum-free medium containing BrdU for 24 hr. The graph shows the mean percentage ± SD of GFP-positive BrdU+ cells.
(C) b4-WT cells expressing GFP alone or in combination with TAM67 or STAT3b were injected orthotopically in the mammary fat pad, and tumor
growth (±SD) was evaluated at the indicated times.
(D) b4-WT cells expressing GFP alone or in combination with TAM67 or STAT3b were cultured on laminin-5 matrix in the presence of 5% FBS. Con-
fluent cultures were stained as indicated. Scale bar = 50 mm.
(E) b4-WT cells infected with the indicated vectors were subjected toMatrigel invasion assay. The graph shows the mean number of invaded cells per
microscopic field (±SD).
(F) b4-WT cells infected with the indicated vectors were injected in the tail vein. Lungs were harvested 19 days later, sectioned, and stained with anti-
GFP. Percentages (±SD) of lung sections occupied by metastases were measured by image analysis.(trastuzumab) could not be used because it does not react
with rat ErbB2.
As shown in Figure 7A, Iressa induced regression of
Neu(YD)/b4-1355T tumors. In contrast, it only reduced
the rate of growth of Neu(YD)/b4-WT tumors (compare
with inset). Consistent with its equal apparent IC50 in
Neu-b4-WT and Neu-b4-1355T cells in vitro (Figure S6),
Iressa suppressed activation of ErbB2 in both types of
tumors (Figure 7B). However, whereas the drug inhibited
tumor cell proliferation to a significant extent in Neu(YD)/
b4-1355T mice, it exerted a more modest inhibitory effect
in Neu(YD)/b4-WT mice (Figure 7C). In addition, it in-
creased tumor apoptosis in Neu(YD)/b4-1355T mice to a
larger extent than it did in Neu(YD)/b4-WT mice, although
overall apoptotic rates were in both cases very low (<1%).498 Cell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc.To examine the specificity of the increased response
of Neu(YD)/b4-1355T tumors to anti-ErbB2 therapy, we
treated tumor-bearing Neu(YD)/b4-WT and Neu(YD)/b4-
1355T mice with the chemotherapeutic drug doxorubicin.
Unlike Iressa, doxorubicin reduced the growth rate of
tumors in Neu(YD)/b4-WT and Neu(YD)/b4-1355T mice
to a similar extent, and it failed to induce tumor regression
in both types of mice (Figure 7A). These results suggest
that b4 signaling specifically promotes resistance to
anti-ErbB2 therapy.
DISCUSSION
Oncogenic mutations disrupt the regulatory circuits that
control cell fate, enabling neoplastic cells to survive and
proliferate at least in part independently of extracellular
cues (Hanahan andWeinberg, 2000). It has been intuitively
argued that neoplastic cells are no longer dependent on
integrin signaling. Our results indicate that b4 signaling
is necessary for tumor cell proliferation and suppression
of apoptosis at the onset of ErbB2-initiated mammary
tumorigenesis but not for normal mammary ductal out-
growth. This suggests that cancer cells transformed by
activated RTKsmay bemore dependent on specific integ-
rin signals for their proliferation and survival than their nor-
mal counterparts. In addition, ablation of all b1 integrins
suppresses polyoma middle T-induced mammary tumor-
Figure 7. b4 Signaling Promotes Resistance to anti-ErbB2
Therapy
(A) Tumor-bearing Neu(YD)/b4-WT (b4-WT) and Neu(YD)/b4-1355T
(b4-1355T) mice were treated with a single dose of doxorubicin
(10 mg/kg) or with Iressa (100 mg/kg/day) or vehicle control (0.1%
Tween 80) for 24 days. The graph shows the mean change in tumor
volume ± SEM at day 24 for Iressa or vehicle alone and at day 21 for
doxorubicin.
(B) Tumor-bearing mice were treated with Iressa (100 mg/kg/day) or
vehicle (0.1% Tween 80) for 9 hr. Equal amounts of total proteins
from tumors were immunoprecipitated with anti-ErbB2 and subjected
to immunoblotting with anti-P-Tyr (PY) or anti-ErbB2.
(C) Tumor-bearing mice were treated with Iressa (100 mg/kg/day) or
vehicle (0.1% Tween 80) for 7 days or more. Tumor sections were
stained with anti-Ki-67 followed by counterstaining with hematoxylin.
Scale bar = 100 mm. The graph shows the mean number of Ki-67+ cells
±SDper low-power field. At least four fields were counted (n = tumors).igenesis (White et al., 2004), suggesting that integrin sig-
naling is also required for neoplastic conversion of cells
transformed by this oncogene. Although additional ge-
netic analyses will be required to fully address the role of
integrin signaling in cancer, this evidence indicates that
the proneoplastic functions of b1 integrins and b4 integrins
are not redundant and that two different oncogenes rely
on cooperating integrin signals to transform cells.
Our molecular studies indicate that ErbB2 combines
with a6b4 and induces sustained phosphorylation of the
b4 signaling domain through activation of SFKs. Con-
versely, b4 supports, through its signaling domain, SFK
activation and association with ErbB2, thereby controlling
phosphorylation of the P loop of ErbB2. These effects
seemingly do not require b4 binding to matrix ligand. De-
letion of the b4 signaling domain uncouples b4 from
ErbB2, disabling SFK-mediated amplification of signaling
and activation of c-Jun and STAT3. Thus, b4 expands
ErbB2 signaling, functioning as a cooperating oncogene
during ErbB2-mediated mammary tumorigenesis.
The b4 integrin promotes mammary carcinoma hyper-
proliferation by inducing phosphorylation and, presum-
ably, activation of c-Jun. The specific mechanisms by
which c-Jun participates in oncogenesis are currently de-
bated (Eferl and Wagner, 2003). Knockin of an unphos-
phorylatable form of c-Jun suppresses formation of skin
papillomas in K5-SOS-F mice and colorectal carcinogen-
esis in ApcMin mice (Behrens et al., 2000; Nateri et al.,
2005). It does not, however, impair chemical carcinogen-
esis in the liver, presumably because phosphorylation of
c-Jun is not required for suppression of p53-dependent
apoptosis (Eferl et al., 2003). Our results link JNK-medi-
ated phosphorylation of c-Jun to oncogenic hyperprolifer-
ation in the mammary gland and identify the b4 integrin as
an activator of this process.
Oncogene-induced hyperproliferation causes apopto-
sis. Several mechanisms operate to overcome this barrier
to transformation in mouse models and human tumors
(Lowe et al., 2004). Deletion of the b4 signaling domain in-
duced apoptosis only in MIN lesions undergoing robust
hyperproliferation, suggesting that b4 signaling protects
mammary tumor cells from oncogene-induced apoptosis.
This prosurvival effect of b4 was particularly evident in
early lesions that had not yet undergone complete luminal
filling, suggesting that there is a temporal window during
which this mechanism operates. Provocatively, loss of
b4 signaling enabled lumen formation in pseudoacinar
structures in Matrigel and caused substantial apoptosis
in pseudoglandular structures in orthotopic tumors. Most
tumor cells that had lost adhesion to the basement mem-
brane underwent apoptosis under these circumstances,
indicating that b4 signaling contributes to luminal filling
also by opposing anoikis. Studies on the HMT-3522
tumor-progression model have linked the prosurvival
effect of a6b4 to its ability to promote assembly of hemi-
desmosomes and epithelial polarity (Weaver et al., 2002)
or to mediate laminin-5 signaling in spite of loss of polarity
(Zahir et al., 2003). Our data do not exclude that suchCell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc. 499
mechanisms may operate in breast cancer cells. They
suggest nevertheless that, in ErbB2-transformed cells,
b4 signaling promotes survival despite loss of adhesion
to the basal lamina and disruption of polarity.
The b4-ErbB2 complex disrupts epithelial adhesion and
promotes invasion in large part through activation of
STAT3. Increasing evidence implicates STAT3 in the de-
velopment of malignancies of the breast and other tissues
(Yu and Jove, 2004). Based on the analysis of mouse
models of skin cancer and anaplastic lymphoma, it has
been proposed that STAT3 contributes to oncogenesis
by promoting cell survival and proliferation (Chan et al.,
2004; Chiarle et al., 2005). Our results link STAT3 to loss
of epithelial adhesion and acquisition of an invasive phe-
notype. Interestingly, inactivation of STAT3 impairs gas-
trulation in zebrafish (Yamashita et al., 2002) and epider-
mal wound healing in mice (Sano et al., 1999), which
require that the participant cells undergo partial or com-
plete EMT. The ability of STAT3 to disrupt epithelial adhe-
sion and polarity documented here may explain its role in
these morphogenetic processes. Together, this evidence
expands the tumorigenic function of STAT3 and suggests
that STAT3 participates in both morphogenesis and tu-
morigenesis by regulating epithelial adhesion and polarity.
Current models suggest that the Par3-Par6 complex
and Rho GTPases regulate epithelial polarity by orches-
trating the assembly of tight junctions (Macara, 2004).
Our results imply that STAT3 activates one or more genes
that encode negative regulators of this polarity pathway or
of the cellular machinery that executes its program. How-
ever, since inhibition of STAT3 induced only partial reas-
sembly of adherens junctions, joint b4-ErbB2 signaling
must disrupt adherens junctions through additional mech-
anisms. In D. melanogaster, loss-of-function mutations in
the polarity genes Dlg, Scrib, or Lgl are sufficient to elicit
invasive tumors similar to human carcinomas (Bilder,
2004). Attempts to separate the growth-suppressive and
polarizing function of these genes have failed, suggesting
that they suppress proliferation by regulating apicobasal
polarity. Our results indicate that the b4-ErbB2 complex
disrupts mammary epithelial polarity and growth control
through distinct signaling mechanisms and, presumably,
transcriptional programs. Similarly, PI-3K controls hyper-
proliferation and disruption of epithelial polarity through
activation of distinct signaling pathways in tumorigenic
HMT-3522 MECs (Liu et al., 2004). These observations
suggest that the signaling pathways controlling polarity
and proliferation have diverged upstreamof polarity genes
in vertebrates. The existence of separate means to control
growth and polarity may have allowed the emergence of
independent checkpoints for these two processes, thus
preventing disruption of tissue architecture and growth
control after a single genetic lesion.
Oncogene-targeted therapies hold great promise in
cancer treatment. Trastuzumab, a monoclonal antibody
that suppresses ErbB2 signaling, slows progression of
ErbB2-positive breast cancers. However, evenwhen com-
bined with standard chemotherapy, this agent is effective500 Cell 126, 489–502, August 11, 2006 ª2006 Elsevier Inc.in only about one-third of patients (Slamon et al., 2001).
Iressa induced regression of mammary tumors in b4-
1355Tmice but not in b4-WTmice, although it suppressed
ErbB2 kinase activity in both types of mice. These results
imply that the b4 integrin activates oncogenic signals that
promote resistance to anti-ErbB2 therapy. Although future
studies are required to elucidate the molecular pathways
causing resistance to Iressa in MMTV-Neu mice and to
determine whether similar mechanisms decrease the
sensitivity of human tumors to ErbB2-targeted therapy,
this study suggests that monoclonal antibodies or other
compounds able to disrupt the b4-ErbB2 complex or b4
signaling may inhibit the progression of ErbB2-positive
breast carcinoma or increase the effectiveness of current
ErbB2-targeted therapies.
EXPERIMENTAL PROCEDURES
Materials and Reagents
See Supplemental Data.
Tumorigenesis Studies
b41355T/1355T mice were backcrossed five times to FVB/n mice and
then bred to FVB/n MMTV-Neu(YD) mice (Dankort et al., 2001).
Neu(YD) lacks four docking sites but retains Y1226 and Y1227, which
mediate recruitment of Shc and transformation through both Grb2-
dependent and -independent mechanisms (Dankort et al., 2001). Tu-
morigenesis studies were performed in nulliparous mice from hetero-
zygous crosses between MMTV-Neu(YD);b4WT/1355T and b4WT/1355T
mice. Tumors were detected by palpation when they reached
2–3 mm in diameter and were recorded without knowledge of geno-
type. For orthotopic transplantation, 5 3 106 cells were suspended in
100 ml of Matrigel diluted 1:1 in PBS and injected into the fat pad of
mammary gland number 3. For experimental metastasis, 1 3 106 or
2 3 106 cells were resuspended in 100 ml PBS and injected into the
tail vein. Iressa tablets were dissolved in 0.1% Tween 80 and adminis-
tered by gastric gavage. Doxorubicin was injected intraperitoneally.
Tumor dimensions were measured by caliper.
Immunostaining
Paraffin-embedded sections were subjected to immunohistochemis-
try with the M.O.M. or VECTASTAIN ABC peroxidase/DAB staining
kits (Vector). Cells and frozen sections were fixed with 4% paraformal-
dehyde for immunofluorescence staining with antibodies to phospho-
JNK, E-cadherin, and b-catenin or with methanol or acetone for immu-
nofluorescence staining with antibodies to ZO-1, b4, and laminin-5.
For BrdU incorporation assays, cells were deprived of serum for
24 hr, cultured in the presence of BrdU for the indicated times, and
stained with the BrdU Labeling and Detection Kit (Roche). At least
300 cells per condition were counted.
Cell Culture
Primary tumor cells were dissociated from tumors by incubation with
2.5 mg/ml dispase and collagenase type I (Invitrogen) for 2–4 hr and
were then plated on collagen I (20 mg/ml) in complete medium. These
cells lost expression of Neu(YD) after three to four passages in culture,
presumably as a result of inactivation of the MMTV LTR promoter. To
verify that b4 also promotes signaling by an activated form of ErbB2
carrying a full complement of cytoplasmic docking sites, these cells
were transduced with pWZL-Neu8142, which encodes oncogenic rat
ErbB2. Hygromycin-resistant cells were then infected with either
LTRH1-b4-WT or LTRH1-b4-1355T and sorted by using Dynabeads
(Dynal Biotech) coated with the anti-b4 mAb 3E1. These tumor cell
lines were cultured in complete medium without EGF. For culture in
3D Matrigel, cells were resuspended at 23 105/ml in SFM and diluted
1:1 with Matrigel.
Biochemical Methods
Cells were lysed in RIPA buffer for immunoblotting and in modified
RIPA buffer for immunoprecipitation (Supplemental Experimental Pro-
cedures). To immunoprecipitate b4, lysates containing 4–5 mg pro-
teins were incubated with 20 mg anti-b4 mAb 3E1 or control anti-
MHC1 mAb W6.32 conjugated to Sepharose beads (Mariotti et al.,
2001). To immunoprecipitate ErbB2, lysates containing 4–5 mg pro-
teins were incubated with 4 mg anti-rat ErbB2 mAb Ab-9 (NeoMarkers)
and 50 ml Protein G. The beads were washed with modified RIPA buffer
without 0.5% DOC prior to SDS-PAGE.
Invasion Assay
Cells (1 3 105) were placed in SFM on Transwell inserts coated with
2 mg of Matrigel. After incubation in wells containing SFM + 10% FBS
for 6 or 7 hr, the inserts were fixed with 4% paraformaldehyde and
stained with crystal violet. Experiments were performed in triplicate.
Statistical Analysis
Kaplan-Meier survival curves were analyzed by using Prism 4 (Graph-
Pad Software), and p values were calculated using the log-rank test.
For assessment of spontaneous metastasis and histological grades,
p values were calculated by using the c2 test. All other p values were
calculated using Student’s t test (unpaired, two-tailed).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, and 13 figures and can be found with this
article online at http://www.cell.com/cgi/content/full/126/3/489/DC1/.
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